| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aac4a747e60a2949ac458ccdbb76fdea |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-608
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-436 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-022 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-16 |
| filingDate |
2011-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d43f27be30923d262037c05c3d1a8715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_306a212ff074458afe717a5b3d5e167d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46f83a23276ac294c4d9bc443c054bdc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41cbe7b093fcd23e19fe70b8618960ff |
| publicationDate |
2013-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2640434-A1 |
| titleOfInvention |
Local vascular delivery of an adenosine a2a receptor agonist / phosphodiesterase inhibitor combination to reduce myocardial injury |
| abstract |
A stent or other implantable medical device for the local delivery of a selective adenosine receptor agonist may be utilized in combination with other therapeutic agents to reduce myocardial injury following an acute myocardial infarction. As soon as possible following an acute myocardial infarction a stent or other suitable device comprising and capable of delivering a selective adenosine receptor agonist is positioned in the blood vessel with the occlusion responsible for causing the infarct. Once in position, the stent or other intraluminal device is deployed to remove the occlusion and reestablish blood flow to the specific area, region or tissue volume of the heart. Over a given period of time the selective adenosine receptor agonist alone or in combination with other therapeutic agents elute from the stent or other device into the downstream coronary blood flow into the hypoxic cardiac tissue for a time sufficient to reduce the level of myocardial injury. |
| priorityDate |
2010-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |